Detalles de la búsqueda
1.
Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies.
Scand J Gastroenterol
; 59(2): 169-175, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-37961895
2.
Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial.
Scand J Gastroenterol
; 56(2): 145-154, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33290108
3.
Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study.
Scand J Gastroenterol
; 54(6): 700-706, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31132014
4.
Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients.
J Pharmacokinet Pharmacodyn
; 46(6): 543-551, 2019 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-31489538
5.
Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies.
Ann Rheum Dis
; 76(7): 1285-1288, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28455438
6.
Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 14(2): 251-8.e1-2, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26545802
7.
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis.
Gastroenterology
; 149(2): 350-5.e2, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25917786
8.
The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
Scand J Gastroenterol
; 50(9): 1110-7, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25865965
9.
Impact of disease location on fecal calprotectin levels in Crohn's disease.
Scand J Gastroenterol
; 50(7): 841-7, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25636819
10.
Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
BioDrugs
; 35(6): 715-733, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34797516
11.
Development of Reliable, Valid and Responsive Scoring Systems for Endoscopy and Histology in Animal Models for Inflammatory Bowel Disease.
J Crohns Colitis
; 12(7): 794-803, 2018 Jun 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-29608662
12.
A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease.
Inflamm Bowel Dis
; 23(4): 650-660, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28195852
13.
Benzimidazoles Promote Anti-TNF Mediated Induction of Regulatory Macrophages and Enhance Therapeutic Efficacy in a Murine Model.
J Crohns Colitis
; 11(12): 1480-1490, 2017 Dec 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28961920
14.
Performance of Common Disease Activity Markers as a Reflection of Inflammatory Burden in Ulcerative Colitis.
Inflamm Bowel Dis
; 22(6): 1384-90, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26978724
15.
Successful Treatment of Oral Crohn's Disease by Ustekinumab.
Inflamm Bowel Dis
; 26(3): e19, 2020 02 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31907551
16.
Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment.
J Crohns Colitis
; 9(11): 973-81, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26116557
17.
Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn's disease.
Inflamm Bowel Dis
; 20(2): 251-8, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24378599
Resultados
1 -
17
de 17
1
Próxima >
>>